- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06373289
Rangos objetivo de oxígeno en bebés con hipertensión pulmonar (PHOX)
Rangos objetivo de saturación de oxígeno en bebés con hipertensión pulmonar asociada a displasia broncopulmonar
Around 50% of infants born extremely preterm develop a chronic lung disease known as bronchopulmonary dysplasia of which some infants will also develop pulmonary hypertension of which 50% of children will die before the age of 2. Physicians are currently limited in their ability to select the most appropriate oxygen targets that will improve outcomes in infants with this condition. This clinical trial will determine whether using different amounts of oxygen improve outcomes in infants with this disease.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Infants born between 22.0 to 31.6 weeks' gestational age with bronchopulmonary dysplasia associated pulmonary hypertension, are receiving supplemental oxygen, and have mature retinas will be randomized to SpO2 targets of either (1) 92-95% (control) or (2) 95-98% (intervention).
Using a cross over design with a 1:1 parallel allocation of infants randomized using a stratified permuted block design. Following 1week of exposure A, infants will cross over to exposure B for 1 week with a 1-week washout period. Bedside providers will follow pre-specified algorithms to maintain oxygen targets during the randomization period. Reports of oxygen saturation performance will also be provided to bedside providers through oxygen saturation histograms.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Samuel Gentle, MD
- Número de teléfono: 205-541-2247
- Correo electrónico: samjgentle@gmail.com
Copia de seguridad de contactos de estudio
- Nombre: Colm Travers
- Correo electrónico: samuel.gentle@yale.edu
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- Reclutamiento
- The University of Alabama at Birmingham
-
Contacto:
- Colm Travers
- Número de teléfono: 205-934-4011
- Correo electrónico: cptravers@uabmc.edu
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510
- Reclutamiento
- Yale New Haven Hospital
-
Contacto:
- Samuel Gentle
- Número de teléfono: 205-541-2247
- Correo electrónico: samuel.gentle@yale.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Between 22w 0/7d and 31w 6/7d gestation at birth
- Diagnosed with echocardiographic pulmonary hypertension (1) >20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index >1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg
- Receiving supplemental oxygen
- Have mature retinas
Exclusion Criteria:
- Major congenital anomalies
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Oxygen saturation target 92-95%
At UAB and Yale oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 92-95% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed to a 1 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets. |
The intervention will be a cross over exposure to the lower oxygen saturation target. |
|
Comparador activo: Oxygen saturation target 95-98%
At UAB and Yale oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 95-98% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed for a 1 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets. |
The intervention will be a cross over exposure to the higher oxygen saturation target. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Intermittent hypoxemia event duration
Periodo de tiempo: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
The average duration of time (in seconds) an infant's oxygen saturation decrease below 80%. |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Echocardiographic shunting
Periodo de tiempo: through study completion, 3 weeks from date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
>20% flow of blood across the PDA from the pulmonary to arterial circulation |
through study completion, 3 weeks from date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Echocardiographic interventricular septal flattening
Periodo de tiempo: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
End-systolic flattening of the interventricular septum (eccentricity index >1.3) |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Echocardiographic tricuspid regurgitation
Periodo de tiempo: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Right ventricular pressure estimates |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Intermittent hypoxemia frequency
Periodo de tiempo: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Number of daily events during which an infant's oxygen saturation decreases below 80% |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Cumulative hypoxemia
Periodo de tiempo: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Daily duration during which an infant's oxygen saturation is <80% |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Brain natriuretic peptide
Periodo de tiempo: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
A polypeptide released from the cardiac ventricles indicative of right heart strain |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Samuel Gentle, Yale University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Infantil, Prematuro, Enfermedades
- Infantil, Recién Nacido, Enfermedades
- Hipertensión
- Lesión pulmonar
- Lesión pulmonar inducida por ventilador
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Hipertensión Pulmonar
- Displasia broncopulmonar
Otros números de identificación del estudio
- 000539476
- 1K23HD113837-01A1 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .